The session was devoted to the topic “Can science help business, and business to the science?”
The speakers of the session were Kunsulu Zakarya, Director General of the Research Institute of Biological Safety Problems, Mukhtar Dzhakishev, ex-head of “Kazatomprom”, Kanat Kopbayev, Managing Director of Kusto Group, Doszhan Zhusupov, founder of the Cerebra startup.
Kunsulu Daltonovna told about the state of Kazakh science and problems, that science needs support not only from the state, but also from business. About the activities of the RIBSP, including the fact that, over 65 years of the institute’s work, scientists have developed more than 70 names of vaccines and test systems against particularly dangerous infections.
In her speech, Kunsulu Daltonovna announced the publication of the results of the 3rd phase of clinical trials, the article “Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in, in healthy adults: A multicentre, randomized, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up” in the highly rated EClinicalMedicine magazine included in the Lancet.
Earlier, the results of phases 1 and 2 of clinical trials of the QazVac vaccine in August 2021 were also published in the journal EClinicalMedicine. The Lancet magazine publishes the results of original research in the field of medicine and healthcare, including the latest achievements in the development and research of vaccines against COVID-19.
Scientists will transfer their developments to the plane of commercialization when they see that they are needed for production, said Kunsulu Daltonovna, addressing all business representatives, expressed readiness to submit their proposals, interact and work for the development and recovery of the economy of Kazakhstan.